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High-dose steroids for the treatment of severe 
COVID-19 pneumonia: the need of the hour? 
To the Editor
Ever since the results of the RECOVERY trial 
[1] were made public, steroids became the main-
stay of the treatment of patients with moderate 
to severe COVID-19 pneumonia needing oxygen 
support. As the pandemic progressed and pa-
tients with moderate to severe disease requiring 
oxygen were treated with 6 mg dexamethasone 
for 10 days, it soon came to light that the recom-
mended dose did not show a significant mortality 
benefit. In clinical practice, high-dose steroids are 
used in disease processes involving high inflam-
matory activity such as auto-immune diseases, 
septic shock unresponsive to fluid resuscitation 
and vasopressors, chronic obstructive pulmonary 
disease (COPD) exacerbation, severe asthma, and 
allergy. Therefore, to consider high-dose steroids 
for the management of severe COVID-19 pneumo-
nia is not a novel concept.
Edara et al. [2] published a case series where 
they treated two patients who were deteriorating 
on conventional regimen of steroid therapy with 
high doses of methylprednisolone reaching up 
to 500–750 mg/day and reported a positive out-
come. So et al. [3] treated seven patients with 
COVID-19 intubated secondary to acute respi-
ratory distress syndrome with high-dose meth-
ylprednisolone 500–1000 mg/day and reported 
a positive recovery in all seven patients. A study 
from Iran [4] randomised sixty-eight hospitalised 
patients with confirmed severe COVID-19 into 
two groups with a ratio of 1:1, with one group 
receiving standard care with the addition of 
methylprednisolone pulse (intravenous injection, 
250 mg/day−1 for 3 days) and the second group 
receiving standard care alone (which included 
the conventional dose of the steroid). The num-
ber of patients with a clinical improvement was 
higher in the group receiving methylprednisolone 
pulse therapy as compared to the group receiving 
standard care (94.1% vs 57.1%), and the mortality 
rate was lower in the methylprednisolone group 
(5.9% vs 42.9%; p < 0.001). These studies, though 
not adequately powered, do raise a possibility 
of benefit to patients with severe disease when 
treated with high doses of steroid.
A question now arises on defining the subset 
of patients who would qualify for the high-dose 
steroid therapy. This query was answered by 
a recent study published by Spanish authors [5] 
to test whether high-dose corticosteroid pulse 
therapy (1.5 mg/kg/24h of methylprednisolone 
or dexamethasone equivalent) was associated 
with increased survival in Covid-19 patients at 
risk of hyper-inflammatory response. The group 
provided with the initial criteria using laboratory 
markers to stratify these patients. The parameters 
proposed were (IL-6 ≥ 40 pg/mL, and/or two of 
the following: C-reactive protein ≥ 100 mg/L, 
D-dimer ≥ 1000 ng/mL, ferritin ≥ 500 ng/mL and 
lactate dehydrogenase ≥ 300 U/L) and a positive 
outcome was noted in the subjects receiving the 
higher doses.
These are times where the scientific knowl-
edge is being updated on a daily basis and guide-
lines are changing every day in the light of new 
evidence. Under such circumstances the sound 
data available showing a benefit of high-dose 
steroids in severe COVID-19 pneumonia and the 
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criteria where they should be instituted warrants 
further investigation in the form of adequately 
powered randomised control trials to answer this 
new but pressing question — is this the need of 
the hour? 
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